Connect with us

Technology

Meihua International Medical Technologies Facilitates World’s Second* 5G Remote Robot-Assisted Lobectomy

Published

on

YANGZHOU, China, July 31, 2024 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced that its NT-2000 surgical path analysis system successfully supported the world’s second* 5G remote robot-assisted lobectomy. This procedure, we believe the first of its kind in China’s Yangzi Delta area, was performed on July 15, 2024, at Yangzhou University Affiliated Hospital by a team from Shanghai Chest Hospital.

“We are honored that our cutting-edge technology could assist the advanced 3D imaging for surgical mapping in this sophisticated procedure,” said Mr. Yongjun Liu, Chairman of Meihua, “Despite a physical distance of over 200 kilometers between the surgical team and the patient, the operation was executed seamlessly in just one hour, thanks to 5G technology and the precision of the robotic surgical system. We believe that robot-assisted surgery has made significant strides due to its clinical effectiveness, low risk, and quick recovery times. We also believe that successful implementations improve the quality of medical services, allowing patients to access diverse, personalized, and high-quality healthcare locally. We anticipate that this innovation will not only ease the workload on medical staff but also address disparities in medical resource distribution across China. Moving forward, Meihua will continue in its efforts to innovate and enhance healthcare outcomes for patients.”

The development of Meihua’s robotic surgical systems is part of the Company’s strategic initiatives to increase sales of high-end products and broaden its customer base. The Company has introduced new overseas technologies, including minimally invasive surgical robot systems, and established a dedicated research and development team focused on robotic-assisted surgery (RAS) systems. The Company believes its NT-2000 system’s real-time monitoring and guidance capabilities enable precise targeting of surgical sites, improving the accuracy and success rates of operations. The RAS project is being developed in conjunction with the Hope City Medical Park in Hainan province, China. The project is expected to be completed in the fall of 2025.

* We believe this is the World’s second 5G remote robot-assisted lobectomy, as reported by Yangzhou University Affiliated Hospital:  https://mp.weixin.qq.com/s/HuApwLs3V8rRib1nSpUMXQ and Yangzhou Daily: http://news.yznews.com.cn/2024-07/27/content_7674119.htm.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips and anal bags, as well as Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for more than 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as more than120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.
Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

IR Department 
Email: secretary@meihuamed.com
Tel: +86-0514-89800199

Christensen 
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548

View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-facilitates-worlds-second-5g-remote-robot-assisted-lobectomy-302210979.html

SOURCE Meihua International Medical Technologies Co., Ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Gamehaus Holdings Inc. to Announce Interim Financial Results for the First Nine Months of Fiscal 2025 on May 19, 2025

Published

on

By

SHANGHAI, May 15, 2025 /PRNewswire/ — Gamehaus Holdings Inc. (“Gamehaus” or the “Company”) (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced that it will release its unaudited financial results for the first nine months of fiscal year 2025 ended March 31, 2025, before the U.S. market opens on May 19, 2025.

The management team of Gamehaus will host a conference call at 08:00 A.M. Eastern Time on Monday, May 19, 2025 (08:00 P.M. Beijing/Hong Kong time on the same day) to discuss the financial results. In advance of the conference call, all participants must use the following link to complete the online registration process. Upon registering, each participant will receive access details for this conference including a conference passcode, a unique PIN number (personal access code), dial-in numbers, and an e-mail with detailed instructions to join the conference call.

Participant Online Registration: https://dpregister.com/sreg/10199786/ff24367338

A live and archived webcast of the conference call will be available on the Company’s Investor Relations website at https://ir.gamehaus.com/.

About Gamehaus

Gamehaus Holdings Inc. is a technology-driven mobile game publisher dedicated to nurturing partnerships with small- and medium-sized game developers to amplify their success. “You make successful games. We make games successful” is the company’s mantra, encapsulating its commitment to transforming potential into prosperity through data-driven monetization support and optimizing game publishing solutions. For more information, please visit https://ir.gamehaus.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s most recent filings with the U.S. Securities and Exchange Commission.

Investor Relations Contact
Gamehaus Holdings Inc.
Investor Relations Team
Email: IR@Gamehaus.com 

The Blueshirt Group
Mr. Jack Wang
Email: Gamehaus@TheBlueshirtGroup.co 

View original content:https://www.prnewswire.com/news-releases/gamehaus-holdings-inc-to-announce-interim-financial-results-for-the-first-nine-months-of-fiscal-2025-on-may-19-2025-302455120.html

SOURCE Gamehaus Holdings Inc.

Continue Reading

Technology

Bridge to Life Announces Abstract Presentations at The 2025 International Congress of the International Liver Transplantation Society (ILTS) in Singapore, May 28-31, 2025

Published

on

By

Abstracts to highlight hypothermic oxygenated perfusion (HOPE) in liver transplants, including pediatric patients

CHICAGO, May 15, 2025 /PRNewswire/ — Bridge to Life™ Ltd., a leader in organ preservation solutions and perfusion technology, today announced the presentation of nine accepted abstracts, including two late-breakers, at the 2025 International Congress of the International Liver Transplantation Society (ILTS). The conference is scheduled to take place in Singapore, from May 28-31, 2025.

Abstracts to be presented:

Late Breaker: Impact of Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: A Donor Age-Stratified Analysis, Marco Maria Pascale, Francesco Frongillo, Giorgia Selvaggi, Giuseppe Bianco, Anna Caltabellotta, Erida Nure, Salvatore Agnes, Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy

Late Breaker: Machine Perfusion in Liver Transplantation: A Game Changer for Middle-Volume Centers?, Marco Maria Pascale, Francesco Frongillo, Giorgia Selvaggi, Giuseppe Bianco, Anna Caltabellotta, Erida Nure, Salvatore Agnes, Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy

Use of HOPE Machine Perfusion for Transplantation in Unusual Scenarios – A Case Report, Alba Bueno, Chris Neophytou, George Clarke, Keith Roberts, Khalid Sharif, Rebeca S. Mateos, Hector Vilca-Melendez, Liver Units, Birmingham Children’s Hospital and Queen Elizabeth Hospital, Birmingham, United Kingdom

Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: Preliminary Results, Ane Andrés, María Velayos, Javier Serradilla Rodríguez, Alba Sánchez-Galán, José Luis Encinas, Paula Burgos, Iñigo Velasco, Jorge Utanda, Esteban Frauca y Francisco Hernandez-Oliveros, Hospital Universitario La Paz, Madrid, Spain

HOPE for Hepatocellular Carcinoma – Recurrence Analysis in Patients Transplanted with Grafts Submitted to Hypothermic Oxygenated Perfusion, Maria João Amaral; Mariana Duque; Júlio Constantino; Pedro Oliveira; João Simões; Ricardo Martins; António Pinho; Emanuel Furtado; José Guilherme Tralhão; Dulce Diogo, Coimbra University Hospital Centre, Coimbra, Portugal

The Impact of HOPE on Liver Transplantation for ACLF and ALF: A Promising Perspective, Pedro Pinto, Mariana Lobo, Andreia Matos, Pedro Oliveira, Dulce Diogo, José Tralhão; Coimbra University Hospital Centre, Coimbra, Portugal

Results of Implementation of Hypothermic Oxygenated Perfusion (HOPE) for Human Liver Grafts before transplantation in a Tertiary Hospital, Andrea González De Godos, Francisco Javier Tejero Pintor, Martín Bailón Cuadrado, José Carlos Sarmentero Prieto, Pilar Pinto Fuentes, Enrique Asensio Diaz, Paloma Lourdes Rodríguez Vielba, Fernando Labarga Rodríguez, David Pacheco Sánchez, Hospital Universitario Rio Hortega, Valladolid, Spain

HOPE for combined Heart and Liver Transplant, Mireia Caralt, José Andrés Molino, Jesús Quintero, Núria Montferrer, Joan Balcells, Cristina Padrós, Maria Margaret Mercadal, Raul Feline Abella,Ferran Gran, Ernest Hidalgo, Hospital Universitari Vall d’Hebron, Barcelona, Spain

HOPE for the hopeless grafts. Experience from a single center, Mireia Caralt, Laura Vidal, Sandra Torres, José Andrés Molino, Marta Martos, Piero Alberti, Cristina Dopazo, Concepción Gómez, Itxarone Bilbao, Ramon Charco, Ernest Hidalgo, , Hospital Universitari Vall d’Hebron, Barcelona, Spain

In addition to the abstract presentations, Bridge to Life will also be participating in the Hands-On Liver Machine Perfusion Workshop taking place on May 28, 2025.  Separate registration is required: 5th ILTS Hands-on Liver Machine Perfusion Workshop – ILTS Congress 2025

Bridge to Life will also be sponsoring a symposium on May 29 at 3:00 pm SST (UTC+8) on “Expanding the Boundaries of Hypothermic Oxygenated Perfusion: Addressing Challenges and Opportunities in the Asia-Pacific Region”.  Speakers include Dr. Sonal Asthana from Aster Hospitals, Dr. Andrea Schlegel from Cleveland Clinic, Ohio and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital, Birmingham.

About Bridge to Life Ltd

Bridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally.

1 VitaSmart is CE Marked and available for sale in several markets outside of the United States. VitaSmart is not approved for sale in the US.

Logo – https://mma.prnewswire.com/media/2085277/Bridge_to_Life_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bridge-to-life-announces-abstract-presentations-at-the-2025-international-congress-of-the-international-liver-transplantation-society-ilts-in-singapore-may-28-31-2025-302455913.html

Continue Reading

Technology

Athean Launches with New AI-Powered Sales Platform to Supercharge Prospecting

Published

on

By

SAN FRANCISCO, May 15, 2025 /PRNewswire/ — Athean, a new AI-driven prospecting and engagement platform, launches today to transform how sales teams win deals. Designed to eliminate tool overload and data silos, Athean centralizes the entire sales ecosystem into one intelligent platform. By streamlining workflows and surfacing actionable insights, Athean supercharges prospecting, enabling teams to easily find and meaningfully engage with high-quality prospects.

“Sales reps are inundated with countless tools for prospecting, valuable data is siloed, and time is lost in the endless switching between platforms,” said John Kim, Co-founder and CEO of Athean. “We created Athean to fill a critical void in the sales technology marketplace – a tool thoughtfully designed to help sales teams deploy their skills more effectively and close better deals faster.”

Athean unifies sales data and tools that reps use daily – from CRMs and prospect databases to communication history – into a single platform, and its AI models arm reps with actionable insights into their accounts. Sales engagement, including calls, emails, and sequences, can also be managed directly in Athean. This seamless access to information enables teams to spend less time gathering data and more time connecting with potential customers.

“Athean isn’t just another prospecting tool; it’s a precise, powerful solution created with the explicit goal of helping individuals master the sales process,” said Kim. “Our intelligent platform provides salespeople with detailed, prioritized insights into their prospect pipeline – who to contact, when, and why – so that they can spend their time on what actually moves deals forward: building relationships.”

Key benefits highlighted in early customer experiences include:

Context: With deep insights into prospects, Athean shines a light on the contacts and context sales teams need to connect meaningfully and efficiently with the right prospects, at the right time.Clarity: Simplified, impactful data presentation integrates seamlessly with your existing tech stack which means less tools and fewer tabs, eliminating the distraction and chaos of prospecting to give sales reps clarity and focus.Connection: We estimate Athean can free up as much as two hours every day, allowing reps to do what they do best: building genuine, lasting relationships.

Athean was originally designed at Silicon Valley security company, Verkada, to be used by their 1,000+ person sales team. Athean will operate as an independent venture of Verkada and is now publicly available to sales teams eager to elevate their prospecting efforts. Learn more at Athean.com.

About Athean
Athean is an AI-driven prospecting and engagement platform that unifies customer and prospect data, communications history, and market signals to transform how sales teams win deals. Athean’s AI-powered tools eliminate tab-switching and manual validation, helping sales reps to identify high potential accounts, surface relevant intel and engage with enriched prospect data – arming your team with the contextual knowledge that builds instant credibility. The result: better conversations, more qualified opportunities, and ultimately, more closed revenue. For more information, please visit www.athean.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/athean-launches-with-new-ai-powered-sales-platform-to-supercharge-prospecting-302456043.html

SOURCE Athean

Continue Reading

Trending